Indication
Postmenopausal Women With Osteoporosis
5 clinical trials
9 products
Product
ProliaProduct
CT-P41Clinical trial
A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women With OsteoporosisStatus: Completed, Estimated PCD: 2023-05-18
Product
MB09Product
EU-ProliaClinical trial
A Randomised, Double-blind, Parallel, Multicentre, Multinational Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 (Proposed Denosumab Biosimilar) Versus Prolia® (EU-sourced) in Postmenopausal Women With Osteoporosis (SIMBA Study)Status: Active (not recruiting), Estimated PCD: 2023-12-14
Product
GP2411Clinical trial
A Randomized, Double-blind, Multicenter Integrated Phase I/III Study in Postmenopausal Women With Osteoporosis to Compare the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety and Immunogenicity of GP2411 (Proposed Biosimilar Denosumab) and Prolia® (EU-authorized)Status: Completed, Estimated PCD: 2022-04-22
Product
BmabClinical trial
A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With OsteoporosisStatus: Active (not recruiting), Estimated PCD: 2024-06-20
Product
Prolia®Product
RomosozumabProduct
AlendronateClinical trial
A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With OsteoporosisStatus: Completed, Estimated PCD: 2017-02-27